NCT04723914

Dual Target CAR-T Cells in B-cell Lymphoma

Clinical Trial of CD19/CD20 Dual Target CAR-T Cells in the Treatment of Relapsed/Refractory B-cell Lymphoma

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: YuLi · Academic / Other
• Sex: All
• Age: 14 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell lymphoma .

Detailed description

Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell lymphoma . Strictly follow the inclusion criteria to screen eligible subjects for inclusion in clinical trials. The selected patients received CD19/CD20 dual-target CAR-T cell therapy. After the treatment is over, follow-up regularly to determine the survival status and follow-up treatment.

Conditions

• Lymphoma, B-Cell
• Relapse/Recurrence
• Refractory Lymphoma
• Dual-target CAR-T Cells

Interventions

Type	Name	Description
BIOLOGICAL	dual target CAR-T cell therapy	CD19/CD20 dual target CAR-T cell therapy

Timeline

• Start date: 2020-10-20
• Primary completion: 2022-12-31
• Completion: 2022-12-31
• First posted: 2021-01-26
• Last updated: 2021-01-26

Locations

1 site across 1 country: China